Use of a Silkworm ( Bombyx mori ) Larvae By-Product for the Treatment of Atopic Dermatitis: Inhibition of NF-κB Nuclear Translocation and MAPK Signaling

• Published in: Nutrients 2023-04, Vol.15 (7), p.1775
• Main Authors: Fan, Meiqi, Choi, Young-Jin, Wedamulla, Nishala Erandi, Zhang, Qun, Kim, Seong Wan, Bae, Sung Moon, Seok, Young-Seek, Kim, Eun-Kyung
• Format: Article
• Language: English
• Subjects: 1-Chloro-2,4-dinitrobenzene; Animal products; Animals; Anti-inflammatory agents; Antibodies; Atopic dermatitis; Bombyx - metabolism; Bombyx mori; By products; Byproducts; Care and treatment; Chemical properties; Cytokines; Cytokines - metabolism; Dermatitis; Dermatitis, Atopic - chemically induced; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - metabolism; Development and progression; Dinitrobenzenes - adverse effects; Dinitrobenzenes - metabolism; Dinitrochlorobenzene; Eczema; Food; Global health; Health aspects; Health services; In vivo methods and tests; Insects; Interleukin 8; Larvae; MAP kinase; Mice; Mice, Inbred BALB C; NF-kappa B - metabolism; NF-κB p65; NF-κB protein; Nuclear transport; Pharmacology; Polymerase chain reaction; Population studies; Protein expression; Proteins; Public health; silkworm by-product; Silkworms; Skin; Skin - metabolism; Skin diseases; Topical application; Translocation; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Yeonnokjam
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu15071775

Atopic dermatitis (AD) is a long-lasting inflammatory skin disease that contributes to the global health burden and impacts 10-20% of the world's population. In this study, we determined the anti-AD effect of a by-product of silkworm ( ) larval powder, strain Yeonnokjam (SLPY), as a sustainable, natural source for the development of therapeutic agents for AD. HaCaT cells were used to assess the in vitro anti-inflammatory activity of SLPY, and a 1-chloro-2,4-dinitrobenzene (DNCB)-induced mouse model was used to study the in vivo anti-AD effects. SLPY treatment downregulated the expression of the inflammatory cytokines TNF-α, IL1β, IL-8, and Cox-2 in stimulated HaCaT cells. Similarly, the topical application of SLPY in DNCB-treated mice downregulated the expression of inflammatory cytokines and proteins while ameliorating the clinical features of AD. Further, SLPY treatment inhibited the nuclear translocation of NF-κb p65, thereby supporting the efficacy of SLPY in the treatment of AD.